MD1920F2 - Compoziţie şi metodă de profilaxie sau frânare a debutului bolii Alzheimer - Google Patents

Compoziţie şi metodă de profilaxie sau frânare a debutului bolii Alzheimer Download PDF

Info

Publication number
MD1920F2
MD1920F2 MD99-0262A MD990262A MD1920F2 MD 1920 F2 MD1920 F2 MD 1920F2 MD 990262 A MD990262 A MD 990262A MD 1920 F2 MD1920 F2 MD 1920F2
Authority
MD
Moldova
Prior art keywords
composititon
alzheimer
prevention
delay
disease origin
Prior art date
Application number
MD99-0262A
Other languages
English (en)
Russian (ru)
Other versions
MD990262A (ro
Inventor
Егон НОВАК
Original Assignee
Форбес-Тек Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Форбес-Тек Инк. filed Critical Форбес-Тек Инк.
Publication of MD990262A publication Critical patent/MD990262A/ro
Publication of MD1920F2 publication Critical patent/MD1920F2/ro

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Invenţia se referă la domeniul medicinei, în special la neurologie şi psihiatrie.Esenţa invenţiei constă în aceea că compoziţia conţine beta-sitosterol, campesterol şi stigmastanol şi suplimentar poate include campestanol, iar metoda se caracterizează prin aceea că mamiferului i se administrează o cantitate terapeutic eficientă de această compoziţie de fitosteroli.
MD99-0262A 1997-12-18 1998-12-18 Compoziţie şi metodă de profilaxie sau frânare a debutului bolii Alzheimer MD1920F2 (ro)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/993,901 US5985936A (en) 1997-12-18 1997-12-18 Method of preventing and delaying onset of Alzheimer's disease and composition therefor
PCT/CA1998/001147 WO1999032097A2 (en) 1997-12-18 1998-12-18 Phytosterol composition for preventing alzheimer's disease

Publications (2)

Publication Number Publication Date
MD990262A MD990262A (ro) 2000-06-30
MD1920F2 true MD1920F2 (ro) 2002-05-31

Family

ID=25540052

Family Applications (1)

Application Number Title Priority Date Filing Date
MD99-0262A MD1920F2 (ro) 1997-12-18 1998-12-18 Compoziţie şi metodă de profilaxie sau frânare a debutului bolii Alzheimer

Country Status (18)

Country Link
US (1) US5985936A (ro)
EP (1) EP0967982A2 (ro)
CN (1) CN1252724A (ro)
AU (1) AU1656099A (ro)
BG (1) BG103740A (ro)
BR (1) BR9807577A (ro)
CA (1) CA2281710A1 (ro)
EE (1) EE9900354A (ro)
GE (1) GEP20022783B (ro)
HU (1) HUP0100737A3 (ro)
LT (1) LT4801B (ro)
LV (1) LV12438B (ro)
MD (1) MD1920F2 (ro)
NO (1) NO993979L (ro)
PL (1) PL335421A1 (ro)
RU (1) RU2173151C2 (ro)
SK (1) SK112999A3 (ro)
WO (1) WO1999032097A2 (ro)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2297860C1 (ru) * 2006-02-07 2007-04-27 Иван Васильевич Максимович Способ эндоваскулярного лечения болезни альцгеймера

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060141036A1 (en) * 1997-12-12 2006-06-29 Andrx Labs Llc HMG-CoA reductase inhibitor extended release formulation
US20020107173A1 (en) * 1999-11-04 2002-08-08 Lawrence Friedhoff Method of treating amyloid beta precursor disorders
WO2001032161A2 (en) * 1999-11-04 2001-05-10 Andrx Corporation Use of a hmg-coa reductase inhibitor for treating amyloid beta precursor disorders
JP4970690B2 (ja) 2000-04-14 2012-07-11 マース インコーポレーテッド 血管の健康状態を改善するための組成物および方法
US6982251B2 (en) * 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US20030013692A1 (en) * 2001-01-19 2003-01-16 Gullans Steven R. Methods of treating neurological disorders
CA2434430A1 (en) 2001-01-26 2002-08-01 Harry R. Davis The use of substituted azetidinone compounds for the treatment of sitosterolemia
ES2274013T3 (es) 2001-01-26 2007-05-16 Schering Corporation Combinaciones de activador(es) del receptor activado por el proliferador de los peroxisomas (ppar) e inhibidor(es)m de la absorcion de estelores y tratamientos para trastornos vasculares.
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
EP1442133B1 (en) * 2001-02-12 2007-12-12 N.V. Organon Use of Mirtazapine for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
US6399310B1 (en) 2001-02-12 2002-06-04 Akzo Nobel N.V. Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
US20030105082A1 (en) * 2001-12-03 2003-06-05 Murphy Greer Marechal Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
AU2002336609B2 (en) 2001-09-21 2006-08-24 Merck Sharp & Dohme Corp. Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors
DE10154221A1 (de) * 2001-11-07 2003-05-15 Max Delbrueck Centrum Mittel zur Behandlung von Läsionen des Nervensystems
WO2004043457A1 (en) 2002-11-06 2004-05-27 Schering Corporation Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
FR2848452B1 (fr) * 2002-12-12 2007-04-06 Aventis Pharma Sa Application des inhibiteurs de recapture intestinale des acides biliaires pour la prevention et le traitement de la maladie d'alzheimer
PL378571A1 (pl) * 2003-02-01 2006-05-02 Neuralab Limited Czynna immunizacja dla wytworzenia przeciwciał przeciw rozpuszczalnemu A-ß
US7235543B2 (en) 2003-03-07 2007-06-26 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
CN1756756A (zh) 2003-03-07 2006-04-05 先灵公司 取代的2－吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
WO2004081004A1 (en) * 2003-03-07 2004-09-23 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
US20080182801A1 (en) * 2003-12-22 2008-07-31 Btg International Limited Core 2 glcnac-t inhibitors
GB0329667D0 (en) * 2003-12-22 2004-01-28 King S College London Core 2 GlcNAc-T inhibitor
GB0513881D0 (en) * 2005-07-06 2005-08-10 Btg Int Ltd Core 2 GLCNAC-T Inhibitors III
AU2005208566A1 (en) * 2004-01-22 2005-08-11 Genaissance Pharmaceuticals, Inc. APOE genetic markers associated with age of onset of Alzheimer's Disease
EP1814575A4 (en) * 2004-11-24 2010-07-07 Neopro Labs Llc METHOD AND COMPOSITIONS FOR TREATING SUFFERING
GB0512726D0 (en) * 2005-06-22 2005-07-27 Btg Int Ltd Multiple sclerosis therapy and diagnosis
GB0513883D0 (en) * 2005-07-06 2005-08-10 Btg Int Ltd Diagnosis of Atherosclerosis
GB0513888D0 (en) * 2005-07-06 2005-08-10 Btg Int Ltd Core 2 GLCNAC-T Inhibitors II
KR20100135847A (ko) * 2008-03-27 2010-12-27 에보텍 뉴로사이언시즈 게엠베하 Ｎｍｄａ ｎｒ２ｂ―서브타입 선택적 길항제를 사용한 질병 치료 방법
WO2010104375A1 (en) * 2009-03-12 2010-09-16 N.V. Nutricia Stigmasterol for the treatment of alzheimer's disease
US10383886B2 (en) 2010-01-11 2019-08-20 Phoenix Biotechnology, Inc. Method of treating neurological conditions with oleandrin
US10307450B2 (en) 2010-01-11 2019-06-04 Phoenix Biotechnology, Inc. Method of treating neurological conditions with extract of Nerium species or Thevetia species
US9011937B2 (en) * 2010-11-22 2015-04-21 Phoenix Biotechnology, Inc. Method of treating neurological conditions with extract of Nerium species or Thevetia species
US9376481B2 (en) 2011-04-26 2016-06-28 The Regents Of The University Of California Methods of promoting CNS neuronal repair by inhibiting LRP-1
CN102813659A (zh) * 2012-08-21 2012-12-12 贵阳中医学院 20α-二甲胺基- 2α-羟基-3β-惕洛酰胺基-5α-孕甾烷的用途
WO2015123618A1 (en) * 2014-02-14 2015-08-20 Arizona Board Of Regents For The University Of Arizona Method for increasing bcl2 gene expression
US10596186B2 (en) 2016-09-14 2020-03-24 Phoenix Biotechnology, Inc. Method and compositions for treating viral infections
US10702567B2 (en) 2016-09-14 2020-07-07 Phoenix Biotechnology, Inc. Method and compositions for treating viral infection
JP7370966B2 (ja) 2017-09-14 2023-10-30 フェニックス・バイオテクノロジー・インコーポレイテッド 神経学的状態を治療するための方法および改善された神経保護組成物
US11331291B2 (en) 2017-09-14 2022-05-17 Phoenix Biotechnology, Inc. Method of and improved composition for treating triterpene-responsive conditions, diseases or disorders
EP3842039A1 (en) * 2019-12-24 2021-06-30 Folium Biosciences Europe B.V. Food supplement comprising cannbinoids and phytosterols for alzheimer
WO2021130002A1 (en) 2019-12-24 2021-07-01 Folium Biosciences Europe B.V. Food supplement for alzheimer
US11806359B2 (en) 2020-03-31 2023-11-07 Phoenix Biotechnology, Inc. Method and compositions for treating Coronavirus infection
CU24748B1 (es) 2022-11-04 2025-04-04 Centro Nac De Biopreparados Nutracéutico para la prevención y tratamiento del deterioro cognitivo

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996010033A1 (en) * 1994-09-29 1996-04-04 The University Of British Columbia Sterol compositions from pulping soap

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2057531C1 (ru) * 1986-07-01 1996-04-10 Всероссийский научный центр по безопасности биологически активных веществ Средство для стимуляции обучения и памяти
IT1203515B (it) * 1987-02-26 1989-02-15 Indena Spa Complessi di saponine con fosfolipidi e composizioni farmaceutiche e cosmetiche che li contengono
SK232890A3 (en) * 1989-05-17 1998-11-04 Pfizer 2-piperidino and 2-pyrrolidino-1-alkanols derivatives and preparation method thereof
CA2150483C (en) * 1992-12-17 1999-09-14 Pfizer Limited Pyrazoles and pyrazolopyrimidines
WO1994018994A1 (en) * 1993-02-23 1994-09-01 Pharmakon Usa, Inc. Therapeutic herbal composition
US5589182A (en) * 1993-12-06 1996-12-31 Tashiro; Renki Compositions and method of treating cardio-, cerebro-vascular and alzheimer's diseases and depression
CN1179903A (zh) * 1996-10-09 1998-04-29 李辉 营养丝米粉
WO1998051302A1 (en) * 1997-05-15 1998-11-19 University Of Washington Composition and methods for treating alzheimer's disease and other amyloidoses

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996010033A1 (en) * 1994-09-29 1996-04-04 The University Of British Columbia Sterol compositions from pulping soap
MD1721C2 (ro) * 1994-09-29 2002-01-31 The University Of British Columbia Procedeu de separare a compoziţiei de fitosteroli din săpun de pulpă, compoziţie de reducere a nivelului de colesterol şi produs terapeutic

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WEISGRABER et al. Lipoproteins, neurobiology, and Alzheimer(s disease: Structure and function of apolipoprotein-E. Curr. Opin. Struct. Biol. 1994, 4, p. 507-515 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2297860C1 (ru) * 2006-02-07 2007-04-27 Иван Васильевич Максимович Способ эндоваскулярного лечения болезни альцгеймера

Also Published As

Publication number Publication date
SK112999A3 (en) 2001-11-06
AU1656099A (en) 1999-07-12
NO993979D0 (no) 1999-08-18
EP0967982A2 (en) 2000-01-05
LV12438B (en) 2000-09-20
NO993979L (no) 1999-10-13
CA2281710A1 (en) 1999-07-01
CN1252724A (zh) 2000-05-10
BR9807577A (pt) 2001-08-07
HUP0100737A2 (hu) 2001-09-28
LT4801B (lt) 2001-06-25
EE9900354A (et) 2000-02-15
LV12438A (en) 2000-03-20
RU2173151C2 (ru) 2001-09-10
PL335421A1 (en) 2000-04-25
WO1999032097A2 (en) 1999-07-01
LT99114A (lt) 2001-01-25
GEP20022783B (en) 2002-09-25
MD990262A (ro) 2000-06-30
WO1999032097A3 (en) 1999-09-02
HUP0100737A3 (en) 2002-07-29
BG103740A (en) 2000-05-31
US5985936A (en) 1999-11-16

Similar Documents

Publication Publication Date Title
MD1920F2 (ro) Compoziţie şi metodă de profilaxie sau frânare a debutului bolii Alzheimer
RU99120072A (ru) Способ и композиция для профилактики и задержки начала болезни Альцгеймера
EP0402950A3 (en) Treatment of postmenopausal disorders
CA2223397A1 (en) Novel nor-pregnanes for inducing hypothalamic effects
MY104535A (en) Oral composition for the treatment of inflammatory bowel diseases.
IL136972A0 (en) Novel anti-estrogenic steroids and associated pharmaceutical compositions and methods of use
AU3254395A (en) Use of a combination product that contains a competitive progesterone antagonist and a gestagen for the production of a pharmaceutical agent for treating endometriosis or leiomyomata uteri
HUP9900147A2 (hu) Terápiás szerek és autoimmun betegségek kezelésére alkalmas gyógyszerkészítmények
HU9503578D0 (en) Androstane steroids as neurochemical initilators of change in human hypothalamic function and related pharmaceutical compositions and methods
CA2389570A1 (en) Methods for treating mild cognitive impairment
CA2258177A1 (en) 19-nor-cholane steroids as neurochemical initiators of change in human hypothalamic function
EP0914165A4 (en) STEROIDS USED AS NEUROCHEMICAL STIMULATORS OF THE VOMERO-NASAL ORGANS AND RELIEVING PREMENSTRUAL AND ANXIETY SYMPTOMS
HU9503579D0 (en) Estrene steroids as neurochemical initiators of change in human hypothalamic function and related pharmaceutical compositions and methods
EP0924219A3 (en) Novel estrenes for inducing hypothalamic effects
ZA965891B (en) Tnf receptor and steroid hormone in a combined therapy
CA2196690A1 (en) Pregnanes and cholanes as neurochemical initiators of change in hypothalamic function
CA2248841A1 (en) Sequential oestrogen/progesterone antagonist combination for hormone replacement therapy
IL126623A0 (en) Pharmaceutical compositions and kits for dhea combined therapy
MXPA94000705A (es) Esteroides de estreno como iniciadores neuroquimicos del cambio en la funcion hipotalamica humana ycomposiciones farmaceuticas y metodos relacionados.
BR9816142A (pt) Esteróides de 19-nor-colano como iniciadores neuroquìmicos de mudança na função hipotalâmica humana